रजिस्ट्री सं. डी.एल.- 33004/99 REGD. No. D. L.-33004/99

भारत का राजपत्र
The Gazette of India

सी.जी.-डी.एल.-अ.-11042021-226507
CG-DL-E-11042021-226507

असाधारण
EXTRAORDINARY

भाग II—खण्ड 3—उप-खण्ड (ii)
PART II—Section 3—Sub-section (ii)

प्राधिकार से प्रकाशित
PUBLISHED BY AUTHORITY

सं. 1437] नई दिल्ली, रविवार, अप्रैल 11, 2021/चैत्र 21, 1943
No. 1437] NEW DELHI, SUNDAY, APRIL 11, 2021/CHAITRA 21, 1943

वाणिज्य एवं उद्योग मंत्रालय

(वाणिज्य विभाग)

(विदेश व्यापार महानिदेशालय)

अधिसूचना

नई दिल्ली, 11 अप्रैल, 2021

सं. 01/2015–2020

विषय : इंजेक्शन रेमडेसिविर और रेमडेसिविर सक्रिय भेषज घटक (एपीआई) की निर्यात नीति में संशोधन।

का.आ. 1548(अ).—विदेश व्यापार नीति, 2015–2020 के पैरा 1.02 और 2.01 के साथ पठित यथा–संशोधित विदेश व्यापार (विकास एवं विनियमन) अधिनियम, 1992 (वर्ष 1992 की संख्या 22) की धारा 3 के तहत प्रदत्त शक्तियों का प्रयोग करते हुए, केन्द्र सरकार एतद्द्वारा रेमडेसिविर और इसके सूत्रणों के निर्यात से संबंधित आईटीसी एचएस निर्यात नीति की अनुसूची 2 में निम्नलिखित संशोधन करती है:

क्र. सं.	आईटीसी एचएसकोड	विवरण	मौजूदा नीति	संशोधित नीति
207एए	ईएक्स 293499 ईएक्स 300490	इंजेक्शन रेमडेसिविर और रेमडेसिविर सक्रिय भेषज घटक (एपीआई)	मुक्त	निषिद्ध

2. विदेश व्यापार नीति (एफटीपी) 2015–20 के पैरा 1.05 के अंतर्गत संक्रमण कालीन यवस्था से संबंधित प्रावधान इस अधिसूचना हेतु लागू नहीं है।

3. इस अधिसूचना का प्रभावः

उपर्युक्त विनिर्दिष्ट आईटीसी एचएस कोड्स अथवा किसी अन्य एचएसकोड के अंतर्गत आने वाले इंजेक्शन रेमडेसिविर और रेमडेसिविर सक्रिय भेषज घटक (एपीआई) का निर्यात तत्काल प्रभाव से निषिद्ध किया गया है।

[फा. सं. 01/91/180/24/एएम–22/ईसी/ई–27724]

अमित यादव, महानिदेशक, विदेश व्यापार
एवं पदेन अपर सचिव

MINISTRY OF COMMERCE AND INDUSTRY

(Department of Commerce)

(DIRECTORATE GENERAL OF FOREIGN TRADE)

NOTIFICATION

New Delhi, the 11th April, 2021

No. 01/2015-2020

Subject : Amendment in Export Policy of Injection Remdesivir and Remdesivir API.

S.O. 1548(E).—In exercise of powers conferred by Section 3 of the Foreign Trade (Development & Regulation) Act, 1992 (No. 22 of 1992), as amended, read with Para 1.02 and 2.01 of the Foreign Trade Policy, 2015-20, the Central Government hereby makes the **following amendment in Schedule 2 of the ITCHS Export policy** related to export of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API):

S. No.	ITC HS Codes	Description	Present Policy	Revised Policy
207AA	Ex 293499 Ex 300490	Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients(API)	**Free**	**Prohibited**

2. The provision under Para 1.05 of the Foreign Trade Policy (FTP) 2015-20 regarding transitional arrangement is not applicable for this notification.

3. Effect of this Notification:

The export of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) falling under the ITCHS Codes specified above or falling under any other HS Code has been prohibited, with immediate effect.

[F. No. 01/91/180/24/AM-22/EC/E-27724]

AMIT YADAV, Director General of Foreign Trade
& Ex-Officio Addl. Secy.

Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.

Ministry of Health and Family Welfare

Centre Prohibits Exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the COVID situation in the country improves

Centre takes Various Steps to ensure easy access of Remdesivir to Patients and Hospitals

Posted On: 11 APR 2021 5:25PM by PIB Delhi

India is witnessing a recent surge in COVID cases. As on 11.04.2021, there are 11.08 lakh active COVID cases and they are steadily increasing. This has led to a sudden spike in demand for Injection Remdesivir used in treatment of COVID patients. There is a potential of further increase in this demand in the coming days.

Seven Indian companies are producing Injection Remdesivir under voluntary licensing agreement with M/s. Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month.

In light of the above, Government of India has prohibited the exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the situation improves.

In addition, Government of India has taken the following steps to ensure easy access of hospital and patients to Remdesivir:

1. All domestic manufactures of Remdesivir have been advised to display on their website, details of their stockists/distributors to facilitate access to the drug.
2. Drugs inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb hoarding and black marketing. The State Health Secretaries will review this with the Drug Inspectors of the respective States/UTs.
3. The Department of Pharmaceuticals has been in contact with the domestic manufacturers to ramp up the production of Remdesivir.

The Government of India has also advised the States that the extant "National Clinical Management Protocol for COVID-19", which is based on evidence, has been developed after many interactions by Committee of Experts, and is the guiding document for treatment of Covid-19 patients. In the Protocol, Remdesivir is listed as an Investigational Therapy, i.e. where informed and shared decision making is essential, besides taking note of contra indications mentioned in the detailed guidelines.

The States and UTs have been advised that these steps should again be communicated to all hospitals, both in public and private sector, and compliance monitored.

****

MV

HFW/Remdesivir Export prohibited/11th April2021/2